Den europeiske union - latvisk - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromīds, formoterol fumarate dihidrāts - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - duakliru genuair ir indicēts kā uzturēšanas bronhodilatatora terapija simptomu mazināšanai pieaugušiem pacientiem ar hronisku obstruktīvu plaušu slimību (hops).

Den europeiske union - latvisk - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - brimica genuair ir indicēts kā uzturējoša bronhodilatatora terapija gaisa plūsmas obstrukcijai un simptomu atvieglošanai pieaugušiem pacientiem ar hronisku obstruktīvu plaušu slimību (hops).

USA - engelsk - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - aclidinium bromide (unii: uqw7uf9n91) (aclidinium - unii:k17vy42f6c) - aclidinium bromide 400 ug - tudorza® pressair® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd). the use of tudorza pressair is contraindicated in the following conditions: risk summary there are no adequate and well controlled studies of tudorza pressair in pregnant women to inform drug associated risks. no adverse developmental effects were seen with inhalation administration of aclidinium bromide to pregnant rats and rabbits during organogenesis at 15 or 20 times, respectively, the maximum recommended human daily inhaled dose (mrhdid). however, reduced pup weights were seen when pregnant rats continued inhalation administration through lactation at 5 times the mrhdid of aclidinium bromide. adverse developmental effects occurred when rabbits were orally dosed with aclidinium bromide at approximately 1,400 times the mrhdid [see data ]. the estimated background risk of major birth defects and miscarriage of the indicated populations is unknown

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - aclidinium bromide, quantity: 0.4 mg/actuation; formoterol fumarate dihydrate, quantity: 0.012 mg/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - brimica genuair 340/12 is indicated as a long-term twice daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - aclidinium bromide, quantity: 0.4 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - bretaris genuair is indicated as a long-term maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

USA - engelsk - NLM (National Library of Medicine)

forest laboratories, inc. - aclidinium bromide (unii: uqw7uf9n91) (aclidinium bromide - unii:uqw7uf9n91) - aclidinium bromide 400 ug

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - aclidinium bromide - inhalation powder - 375microgram/1dose

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

niche pharma ltd - aclidinium bromide - inhalation powder - 375microgram/1dose

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - aclidinium bromide - inhalation powder - 375microgram/1dose

Israel - engelsk - Ministry of Health

astrazeneca (israel) ltd - aclidinium bromide - powder for inhalation - aclidinium bromide 0.4 mg - aclidinium bromide - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)